XSHG
600085
Market cap7.11bUSD
Jun 06, Last price
37.24CNY
1D
-0.59%
1Q
2.39%
Jan 2017
18.79%
Name
Beijing Tongrentang Co Ltd
Chart & Performance
Profile
Beijing Tongrentang Co., Ltd engages in the scientific research, production, sale, and distribution of Chinese medicines in China and internationally. It covers product formulations, such as pills, powders, wines and capsules, oral liquids, and dripping pills with the original powder preparation in the areas of cardiovascular, cerebrovascular, and gynecological diseases, as well as anti-depressive new drugs. The company sells its products under the brand names of Angong Niuhuang series, Tongren Niuhuang Qingxin series, Tongren Dahuoluo series, Yufeng Ningxin dripping pills, Hemiplegia recovery pills, etc. The company is based in Beijing, China. Beijing Tongrentang Co., Ltd operates as a subsidiary of China Beijing Tongrentang (Group) Co., Ltd.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 18,597,282 4.12% | 17,860,891 16.19% | 15,372,423 5.27% | |||||||
Cost of revenue | 12,446,700 | 11,253,532 | 11,444,700 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 6,150,582 | 6,607,360 | 3,927,724 | |||||||
NOPBT Margin | 33.07% | 36.99% | 25.55% | |||||||
Operating Taxes | 525,046 | 497,429 | 517,547 | |||||||
Tax Rate | 8.54% | 7.53% | 13.18% | |||||||
NOPAT | 5,625,536 | 6,109,931 | 3,410,177 | |||||||
Net income | 1,526,275 -8.54% | 1,668,835 -24.12% | 2,199,391 16.32% | |||||||
Dividends | (483,095) | (397,726) | ||||||||
Dividend yield | 0.66% | 0.65% | ||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 187,721 | 93,025 | 795,422 | |||||||
Long-term debt | 3,762,090 | 3,561,244 | 2,943,340 | |||||||
Deferred revenue | 169,386 | 157,568 | 153,956 | |||||||
Other long-term liabilities | 5,859 | 167,097 | 9,475 | |||||||
Net debt | (6,901,674) | (8,503,430) | (7,913,355) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 760,985 | 1,869,492 | 3,094,296 | |||||||
CAPEX | (324,515) | |||||||||
Cash from investing activities | (313,165) | |||||||||
Cash from financing activities | (1,438,031) | |||||||||
FCF | 3,695,396 | 5,059,702 | 3,721,715 | |||||||
Balance | ||||||||||
Cash | 10,756,681 | 12,132,267 | 11,624,415 | |||||||
Long term investments | 94,804 | 25,432 | 27,702 | |||||||
Excess cash | 9,921,621 | 11,264,655 | 10,883,496 | |||||||
Stockholders' equity | 17,462,324 | 17,052,504 | 16,630,984 | |||||||
Invested Capital | 13,846,208 | 11,748,071 | 10,193,632 | |||||||
ROIC | 43.96% | 55.69% | 32.90% | |||||||
ROCE | 25.86% | 28.70% | 18.63% | |||||||
EV | ||||||||||
Common stock shares outstanding | 1,371,470 | 1,370,973 | ||||||||
Price | 40.59 -24.41% | 53.70 20.19% | 44.68 -0.67% | |||||||
Market cap | 73,647,953 20.23% | 61,255,065 -0.70% | ||||||||
EV | 72,343,617 | 59,988,502 | ||||||||
EBITDA | 7,122,037 | 7,522,632 | 4,813,316 | |||||||
EV/EBITDA | 9.62 | 12.46 | ||||||||
Interest | 133,760 | 119,676 | 111,398 | |||||||
Interest/NOPBT | 2.17% | 1.81% | 2.84% |